Merck Initiates Phase 2 Trial of MK-6194 in Vitiligo
Merck is recruiting for a Phase 2 trial of MK-6194, a novel investigational interleukin-2 mutein (IL-2M) inhibitor in patients with non-segmental vitiligo. Administered via a subcutaneous injection, MK-6194 selectively expands regulatory T cells without activating cytotoxic immune cell counterparts. IL-2M is a protein that helps regulate the body’s immune response, and MK-6194’s mechanism may help […]